Marc Beer is the co-founder and serving Chief Executive Officer of Renovia Inc., a medical technology company. Marc co-founded the company alongside Ramon Iglesias and Yolanda Lorié in 2016. Since the inception of Renovia, Marc has utilized his in-depth knowledge and skills in the development and commercialization of medical products and devices to put the company in the forefront as a leader in the diagnosis, care, and treatment of pelvic floor disorders.
Marc beer has brought his 25 years of experience into the company. Before co-founding Renovia, he served as the founding Chief Executive Officer of Viacell. In seven years, Marc transformed ViaCell from a humble startup to a robust corporate organization. He oversaw the company grow to over 300 employees, eventually going public in 2005. Ultimately, PerkinElmer, impressed by the spectacular performance, acquired ViaCell in 2007.
While still serving as the CEO of ViaCell, Marc Beer served in the management board of Erytech Pharma, a leading biopharmaceutical firm.
Before joining ViaCell, Marc worked at Genzyme, where he held several leadership positions. He served as the Vice President of Global Marketing and is remembered for his pioneering role in the development and global commercialization of medical products to treat rare disease populations. He studied at Miami University, where he graduated with Bachelors of science degree.
Since its inception, Renovia has taken a leading role in the development and commercialization of medical products for diagnosis and treatment of pelvic floor disorders. The company has relentlessly worked to improve the lives of more than 250 million women, who have been suffering from urinary incontinence as a result of weakened pelvic floor muscles.
Renovia has also come up with a unique tailor-made and cost- friendly way of treating pelvic floor disorders. The company uses a combination of Food and Drug Administration certified medical devices and patient-centered data management and mobile app technology. According to Marc Beer, the company’s vision is to restore dignity and health in women across the world.
Barely a year after Renovia’s masterpiece pelvic disorder treatment and diagnosis product, Leva, was approved by the Food and Drugs Administration, Marc beer has secured a total of $42 million in a new round of funding. The financing comprised of $32 million in series B funding and an additional $10 million in venture debt.
Longwood Fund, a previous partner of Renovia, led the series B round. Ascension Ventures and Perceptive Advisors managed the fundraising effort, which included other participants like the OSF Ventures and Western Technology Investment.
Speaking during the announcement of the financing, Mark Beer expressed his appreciation of the support.
“As a company, we are deeply grateful for the support accorded by our partners. The participation is an expression of their confidence in the good work of Renovia. We promise to continue with research and development of innovative products to eliminate pelvic floor disorders,” said Marc. Learn more: https://www.crunchbase.com/person/marc-beer